Bispecific Antibody Application in Pulmonary and Respiratory Disease

Creative Biolabs features a superior antibody engineering platform for developing novel bispecific antibodies (BsAb) for the therapy of receptor signaling interference in lung and respiratory illnesses.

Introduction to Pulmonary and Respiratory Disease

Pulmonary and respiratory diseases vary from the common cold, influenza, and pharyngitis to potentially fatal conditions such as bacterial pneumonia, acute asthma, and lung cancer. Abnormal immune reactions, excessive inflammation, and/or a disordered wound-healing process cause or worsen a variety of pulmonary and respiratory disorders. For example, Th2 and Th17 polarized immune responses, are the primary mediators of allergic asthma; severe neutrophilic asthma is caused by T-cell and ILC3 production of IL17A/F and IL22 (RORc-dependent); and idiopathic pulmonary fibrosis, a progressive fibrotic disease of the lungs, has been identified to be caused by an abnormal wound healing process and associated inflammation in the pulmonary interstitium.

Advantages and Applications of BsAbs in Pulmonary and Respiratory Disease

The use of therapeutic antibodies to treat lung cancer and asthma is a breakthrough that opens up new avenues for the treatment of respiratory disorders. However, due to biological redundancy, cells frequently have escape paths. As BsAbs are bispecific, they can be used to simultaneously target a primary target and an escape pathway, or to block the same pathway in two locations, enhancing therapeutic efficacy.

BsAbs that inhibit proinflammatory cytokines or fibroblast factors can alleviate or even cure pulmonary and respiratory illnesses. In a preclinical in vivo model, an IgG-like T-cell engaging bispecific antibody (ITE) targeting DLL3 and CD3 can cause purely DLL3-dependent T-cell guided lysis of tumor cells and recruitment of T-cells into noninflamed tumor tissues, resulting in small cell lung cancers (SCLC) regression. Furthermore, a bispecific single-domain antibody that can bind two highly conserved regions on a single SARS-CoV-2 variant's Omicron receptor-binding domain is shown to be effectively delivered to the lung via inhalation administration and exhibits exquisite neutralization breadth and therapeutic efficacy in mouse models of SARS-CoV-2 infections. BsAbs targeting IL-4R and IL-5, as well as a combination of monospecific antibodies, have been shown to reduce eosinophilia, IgE production, goblet cell metaplasia, and bronchial hyperreactivity in asthma patients.

Our Services

Creative Biolabs rises to the top of the BsAb services market after years of hard labor. We offer professional services for developing various formats of BsAbs to treat pulmonary and respiratory disorders.